Last Name


John Somberg to Risk Assessment

This is a "connection" page, showing publications John Somberg has written about Risk Assessment.

Connection Strength
  1. Somberg JC, McEwen P, Molnar J. Assessment of cardiovascular and noncardiovascular medical device recalls. Am J Cardiol. 2014 Jun 01; 113(11):1899-903.
    View in: PubMed
    Score: 0.511
  2. Somberg JC. Risk assessment, drug approval, and liability. Am J Ther. 2006 May-Jun; 13(3):181-2.
    View in: PubMed
    Score: 0.296
  3. Somberg JC. Guidelines for a new year. Am J Ther. 2014 Jan-Feb; 21(1):1.
    View in: PubMed
    Score: 0.126
  4. Somberg JC. Flecainide: safety and efficacy. Cardiology. 2008; 111(2):82.
    View in: PubMed
    Score: 0.084
  5. Nada A, Somberg J. First-in-Man (FIM) clinical trials post-TeGenero: a review of the impact of the TeGenero trial on the design, conduct, and ethics of FIM trials. Am J Ther. 2007 Nov-Dec; 14(6):594-604.
    View in: PubMed
    Score: 0.082
  6. Somberg JC. The new drug evaluation process: risk benefit ratio. Am J Ther. 2005 May-Jun; 12(3):199-200.
    View in: PubMed
    Score: 0.069
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.